论文部分内容阅读
目的回顾性分析地西他滨联合低剂量HAG方案和单用HAG方案治疗骨髓增生综合征(MDS)的临床疗效和安全性。方法所有患者按其治疗方案分组,联合组应用地西他滨联合低剂量HAG化疗,HAG组应用最佳剂量化疗;比较两组患者的治疗有效率、生存期及不良反应。结果联合治疗组的有效率显著高于HAG组(P<0.05),无病生存期显著长于HAG组(P<0.05),两组总体生存期无明显差异(P>0.05),联合治疗组的不良反应率明显低于HAG组(P<0.05)。结论使用地西他滨联合低剂量HAG化疗后患者的临床疗效显著、无病生存期较长,不良反应率明显下降。
Objective To retrospectively analyze the clinical efficacy and safety of decitabine combined with low dose HAG regimen and single HAG regimen in the treatment of myelodysplastic syndrome (MDS). Methods All patients were grouped according to their treatment regimen. Decitabine combined with low dose HAG chemotherapy was given in combination group. HAG group was given the best dose of chemotherapy. The treatment efficiency, survival time and adverse reactions in both groups were compared. Results The effective rate of combination therapy group was significantly higher than that of HAG group (P <0.05), disease-free survival was significantly longer than that of HAG group (P <0.05), there was no significant difference in overall survival between the two groups (P> 0.05) Adverse reaction rate was significantly lower than HAG group (P <0.05). Conclusion The clinical efficacy of decitabine in combination with low-dose HAG chemotherapy is significant, the disease-free survival is longer, and the rate of adverse reactions is significantly decreased.